PRESS: Fierce Biotech - Forge Biologics

PRESS: Fierce Biotech

Six months after departing Abeona, Tim Miller, Ph.D., is on his next chapter: Forge Biologics, a gene therapy biotech that’s providing manufacturing and development services to other companies while working on its own pipeline. To fuel this dual mission, Forge picked up $40 million from the Perceptive Xontogeny Venture Fund and Drive Capital.

Forge is the brainchild of Miller and a “confluence of gene therapy experts” who saw a widening gap between the growth of the industry’s gene therapy pipeline and its capacity to actually manufacture the treatments, Miller told Fierce Biotech.

Read in full at

0/5 (0 Reviews)